Investigational drug · Phase 3
HSK39297
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Haemoglobinuria (PNH).
Phase 3Last checked: Nov 20, 2026Latest source record: May 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
2 still active
All registered trials
11
Any phase or sponsor naming "HSK39297"
First trial start
2024
Jul 17, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HSK39297", any sponsor or status.
Conditions studied
As listed on its trial records.
- IgA Nephropathy (IgAN)
- Paroxysmal Nocturnal Hemoglobinuria
- Paroxysmal Nocturnal Haemoglobinuria (PNH)
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- PNH
Approved drugs for the same conditions: Paroxysmal nocturnal hemoglobinuria · IgA nephropathy · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "HSK39297" as an intervention, largest first.
- Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANPivotal-lookingRecruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07390123 · 370 participants (planned) · Start Apr 7, 2026 · Primary completion Dec 2027
Drug: HSK39297; Placebo · For: IgA Nephropathy (IgAN)
Sites: Huangshan City, China; Wuhu, China; Beijing, China · 9 sites in all
- Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LNPivotal-lookingRecruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07363460 · 105 participants (planned) · Start Nov 18, 2025 · Primary completion Nov 5, 2027
Drug: HSK39297 200mgQD; HSK39297 300mgQD and 1 more · For: Lupus Nephritis (LN)
Sites: Nanjing, China
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06350279 · 96 participants · Start Dec 25, 2023 · Primary completion Aug 2, 2024
Drug: HSK39297 · For: Healthy
Sites: Beijing, China
- Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANCompleted
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06670352 · 87 participants · Start Oct 12, 2024 · Primary completion Dec 20, 2025
Drug: Placebo; HSK39297 50mgBID and 2 more · For: IgA Nephropathy (IgAN)
Sites: Beijing, China; Nanjing, China
- A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor TherapyPivotal-lookingCompleted
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06799546 · 73 participants · Start Feb 13, 2025 · Primary completion Nov 5, 2025
Drug: HSK39297 tablets; Eculizumab Injection · For: PNH
Sites: Nanjing, China; Hangzhou, China
- A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA NephropathyRecruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07616700 · 73 participants (planned) · Start Aug 25, 2025 · Primary completion Dec 5, 2026
Drug: HSK39297 200mgQD; HSK39297 300mgQD · For: IgA Nephropathy (IgAN)
Sites: Beijing, China · 2 sites in all
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06561841 · 47 participants · Start Jul 17, 2024 · Primary completion Apr 2, 2025
Drug: HSK39297 · For: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Sites: Nanjing, China
- Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal HemoglobinuriaRecruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06745622 · 47 participants (planned) · Start Jan 3, 2025 · Primary completion Jun 2027
Drug: HSK39297 tablets · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Nanjing, China
- Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With AnemiaPivotal-lookingCompleted
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07052838 · 36 participants · Start May 12, 2025 · Primary completion Dec 23, 2025
Drug: HSK39297 tablets · For: Paroxysmal Nocturnal Haemoglobinuria (PNH)
Sites: Nanjing, China; Hangzhou, China
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07152288 · 24 participants (planned) · Start May 29, 2025 · Primary completion Sep 2025
Drug: HSK39297 tablets; HSK39297 tablets and 1 more · For: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of HSK39297 monotherapy in patients with paroxysmal nocturnal hemoglobinuria.
Gong Y, Zhang L, Zhu Z, et al. · Chin Med J (Engl) 2026
- Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of HSK39297 in Chinese Healthy Subjects: A Phase 1 Clinical Trial.
Dai Y, Wu F, Ni S, et al. · Clin Transl Sci 2025
Also in development for IgA Nephropathy (IgAN)
- FUB523zigakibart, BION-1301Phase 36 trials
Novartis · IgA Nephropathy, Immunoglobulin A Nephropathy, IgA Nephropathy (IgAN)
- MY008211APhase 35 trials
Wuhan Createrna Science and Technology Co., Ltd · Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN)
- JADE101Phase 32 trials
Jade Biosciences, Inc. · IgA Nephropathy (IgAN), IgA Nephropathy
- SC0062Phase 31 trial
Biocity Biopharmaceutics Co., Ltd. · IgA Nephropathy (IgAN)
- HSK39297 200mgQDPhase 23 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Lupus Nephritis (LN)
- HSK39297 300mgQDPhase 22 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Lupus Nephritis (LN)
- SGB-9768Phase 22 trials
Suzhou Sanegene Bio Inc. · PNH - Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN), C3 Glomerulopathy
- SLN12140Phase 22 trials
Linno Pharmaceuticals, Inc. · IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria (PNH)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.